Evidence map›Paper›PMID 35798767›Full record

ArticleScientific reports2022

Identification of early biomarkers in saliva in genetically engineered mouse model C(3)1-TAg of breast cancer.

Isadora Fernandes Gilson Sena, Larissa Lessi Fernandes, Leonardo Lima Lorandi, Thais Viggiani Santana, Luciana Cintra, Ismael Feitosa Lima, Leo Kei Iwai, Jill M Kramer, Alexander Birbrair, Débora Heller

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Omics-Based Investigations of Breast Cancer.Molecules (Basel, Switzerland) · 2023
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 8 institutions in 2 countries.

Isadora Fernandes Gilson Sena *Department of Pathology, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
Larissa Lessi Fernandes *Post Graduate Program in Dentistry, Cruzeiro do Sul University, São Paulo, Brazil.
Leonardo Lima LorandiHospital Israelita Albert Einstein, São Paulo, Brazil.
Thais Viggiani SantanaInstitute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
Luciana CintraHospital Israelita Albert Einstein, São Paulo, Brazil.
Ismael Feitosa LimaLaboratory of Applied Toxicology, Center of Toxins, Immune-Response and Cell Signaling (LETA/CeTICS), Instituto Butantan, São Paulo, Brazil.
Leo Kei IwaiLaboratory of Applied Toxicology, Center of Toxins, Immune-Response and Cell Signaling (LETA/CeTICS), Instituto Butantan, São Paulo, Brazil.
Jill M KramerDepartment of Oral Biology, School of Dental Medicine, The University of Buffalo, State University of New York, Buffalo, NY, USA.
Alexander BirbrairDepartment of Pathology, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil. birbrair@wisc.edu.
Débora HellerPost Graduate Program in Dentistry, Cruzeiro do Sul University, São Paulo, Brazil. debora.heller@cruzeirodosul.edu.br.
Hospital Israelita Albert Einstein · BRInstituto Butantan · BRColumbia University Irving Medical Center · USThe University of Texas Health Science Center at San Antonio · USUniversidade Cruzeiro do Sul · BRUniversidade de São Paulo · BRUniversidade Federal de Minas Gerais · BRUniversity at Buffalo, State University of New York · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer is one of leading causes of death worldwide in the female population. Deaths from breast cancer could be reduced significantly through earlier and more efficient detection of the disease. Saliva, an oral fluid that contains an abundance of protein biomarkers, has been recognized as a promising diagnostic biofluid that is easy to isolate through non-invasive techniques. Assays on saliva can be performed rapidly and are cost-effective. Therefore, our work aimed to identify salivary biomarkers present in the initial stages of breast cancer, where cell alterations are not yet detectable by histopathological analysis. Using state-of-the-art techniques, we employed a transgenic mouse model of mammary cancer to identify molecular changes in precancerous stage breast cancer through protein analysis in saliva. Through corroborative molecular approaches, we established that proteins related to metabolic changes, inflammatory process and cell matrix degradation are detected in saliva at the onset of tumor development. Our work demonstrated that salivary protein profiles can be used to identify cellular changes associated with precancerous stage breast cancer through non-invasive means even prior to biopsy-evident disease.

Indexed as

Precancerous ConditionsSalivaAnimalsBiomarkersBiomarkers, TumorBiopsyFemaleMiceSalivary Proteins and PeptidesBiomarkersBiomarkers, TumorSalivary Proteins and Peptides

Identifiers

PMID35798767
PMCPMC9263110
OpenAlexW4284884901

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.